Pfizer (PFE) AI Stock Analysis

• Market Cap: $139.52B
• Dividend Yield: 6.97%
• Average Volume (3M): 41.94M
• Price to Earnings (P/E): 13.2
• Beta (1Y): 0.36
• Revenue Growth: 14.72%
• EPS Growth: N/A
• Country: US
• Employees: 81,000
• Sector: Healthcare
• Sector Strength: 49
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.78
• Shares Outstanding: 5,685,550,300
• 10 Day Avg. Volume: 37,520,139
• 30 Day Avg. Volume: 41,944,046
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.34
• Enterprise Value/Revenue: 2.93
• Enterprise Value/Gross Profit: 4.35
• Enterprise Value/Ebitda: 8.21
• 1Y Price Target: $28.08
• Price Target Upside: 14.43% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 15

• Rating: 78 Outperform
• Price Target: $28.00 ▲(14.10% Upside)

Pfizer's strong financial performance and positive earnings call are the most significant factors driving the stock score. The company's robust cash flow and strategic R&D advancements support long-term growth. Technical analysis and valuation provide additional support, though mixed signals in technical indicators and competitive pressures in oncology present challenges.

Positive Factors

Earnings Guidance

Pfizer raised its EPS guidance midpoint for 2025, reflecting confidence in future financial performance.

Financial Performance

Pfizer reported EPS that was 36% above consensus expectations, driven by higher revenues and lower-than-anticipated R&D spending.

Stock Valuation

Pfizer shares are viewed as undervalued with potential for better fundamentals, top-line growth, and margin expansion compared to U.S. BioPharma peers.

Negative Factors

Acquisition Challenges

Pfizer's acquisition of Global Blood Therapeutics has proven disappointing with inclacumab's failure and Oxbryta's withdrawal from the market.

Competition and Market Dynamics

The long-term outlook for many of Pfizer's larger franchises remains uncertain due to upcoming patent expiries and competitive threats.

Revenue Uncertainty

A sustained re-rate will require better visibility on structural questions around aging franchises amidst ongoing uncertainty on the revenue contribution.

Pfizer Business Overview & Revenue Model

Company Description

Pfizer Inc. is a multinational pharmaceutical corporation headquartered in New York City, primarily engaged in the research, development, manufacturing, and marketing of healthcare products. The company operates in several sectors, including pharmaceuticals, vaccines, and consumer healthcare. Pfizer's core products encompass a wide range of therapeutic areas, including oncology, cardiology, immunology, and infectious diseases, with notable offerings such as the COVID-19 vaccine, Prevnar for pneumonia, and a variety of prescription medications.

How the Company Makes Money

Pfizer generates revenue primarily through the sale of prescription medicines and vaccines. The company's revenue model is largely driven by its extensive portfolio of patented drugs, which allows it to charge premium prices. Key revenue streams include sales from its innovative therapies, as well as established brands that continue to perform well in the market. Pfizer also earns revenue from collaborations and partnerships, such as its alliance with BioNTech for the development of the COVID-19 vaccine, which significantly boosted its earnings. Additionally, Pfizer benefits from licensing agreements and royalties associated with its research and development efforts. The company's ability to navigate patent expirations and introduce new products is critical for sustaining its revenue growth.

Pfizer Financial Statement Overview

Summary

Pfizer demonstrates strong financial health across its income statement, balance sheet, and cash flow statement. The company shows solid profitability and cash generation, with manageable leverage levels. While there are some concerns about increasing debt and slight operational efficiency pressures, the overall financial position remains strong, supporting continued growth and stability.

Income Statement

Pfizer's income statement shows strong profitability with a gross profit margin of 74.09% and a net profit margin of 16.83% for the TTM period. Revenue growth is positive at 2.19%, indicating a recovery from previous declines. The EBIT and EBITDA margins are healthy at 15.14% and 27.78%, respectively, reflecting efficient operations. However, the decline in EBIT margin from the previous year suggests some pressure on operational efficiency.

Balance Sheet

The balance sheet is solid with a debt-to-equity ratio of 0.70, indicating a manageable level of leverage. Return on equity is 11.95%, showing decent profitability relative to shareholder equity. The equity ratio stands at 43.03%, suggesting a strong equity base. However, the increase in total debt over the years could pose a risk if not managed carefully.

Cash Flow

Pfizer's cash flow statement is robust, with a free cash flow growth rate of 10.86% in the TTM period. The operating cash flow to net income ratio is 0.40, and the free cash flow to net income ratio is 0.82, indicating strong cash generation relative to earnings. The company has improved its free cash flow position significantly, enhancing financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	63.83B	63.63B	59.55B	100.33B	81.29B	41.65B
Gross Profit	42.99B	41.85B	30.34B	62.09B	46.88B	29.88B
EBITDA	22.77B	18.13B	9.56B	41.03B	30.79B	13.17B
Net Income	10.73B	8.02B	2.13B	31.36B	22.15B	9.16B
Balance Sheet
Total Assets	206.09B	213.40B	226.50B	197.21B	181.48B	154.23B
Cash, Cash Equivalents and Short-Term Investments	13.25B	20.48B	12.69B	22.73B	31.07B	12.22B
Total Debt	61.80B	63.65B	70.84B	34.86B	37.00B	38.27B
Total Liabilities	117.08B	124.90B	137.21B	101.29B	104.01B	90.76B
Stockholders Equity	88.69B	88.20B	89.01B	95.66B	77.20B	63.24B
Cash Flow
Free Cash Flow	12.44B	9.84B	4.79B	26.03B	29.87B	11.61B
Operating Cash Flow	15.19B	12.74B	8.70B	29.27B	32.58B	14.40B
Investing Cash Flow	3.54B	2.65B	-32.28B	-15.78B	-22.55B	-4.27B
Financing Cash Flow	-18.17B	-17.14B	26.07B	-14.83B	-9.82B	-9.65B

Pfizer Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 24.54
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PFE, the sentiment is Negative. The current price of 24.54 is below the 20-day moving average (MA) of 24.98, below the 50-day MA of 24.62, and above the 200-day MA of 24.19, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 46.35 is Neutral, neither overbought nor oversold. The STOCH value of 19.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PFE.

Pfizer Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MRK	79 Outperform	$209.94B	12.98	35.44%	3.81%	2.00%	20.01%
PFE	78 Outperform	$139.52B	13.18	12.16%	6.97%	14.72%	―
NVS	78 Outperform	$239.55B	18.22	32.82%	3.11%	12.38%	-12.67%
JNJ	78 Outperform	$428.83B	19.04	30.21%	2.84%	4.69%	34.88%
ABBV	75 Outperform	$374.37B	100.85	112.90%	3.04%	6.05%	-29.75%
AMGN	67 Neutral	$150.80B	23.22	99.14%	3.35%	13.10%	110.67%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%

Pfizer Corporate Events

Pfizer Completes €3.3 Billion Notes Offering

On May 19, 2025, Pfizer Netherlands International Finance B.V., a subsidiary of Pfizer Inc., completed a public offering of €3.3 billion in aggregate principal amount of notes with varying maturity dates and interest rates. This strategic financial move, backed by a senior unsecured guarantee from Pfizer Inc., is part of the company’s broader financial strategy to strengthen its market position and ensure operational liquidity.